European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)

July 8, 2025—According to a press release from Oncopeptides, "its drug Pepaxti has been included in new clinical practice guidelines from EHA-EMN* for patients with relapsed, refractory multiple myeloma. This marks an important recognition by leading experts of the drug’s clinical value and ability to meet an unmet medical need in the treatment of this serious blood cancer."

Experts reviewed strong clinical evidence to create these treatment guidelines. For patients whose myeloma no longer responds to the three main types of treatment (triple-class refractory or exposed), Pepaxti is recommended. This is backed by the highest level of evidence and given a Grade B recommendation.

Pepaxti is also recommended for patients with more advanced myeloma whose disease relapses after treatment with CAR-T cell therapy or antibody-drug conjugates (ADC), and no longer responds to four types of myeloma drugs.

For more information about these clinical practice guidelines, read the full press release from the button below: